A multicenter German study assessing outcome and associated factors in lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Molnupiravir (Primary) ; Remdesivir (Primary) ; Sotrovimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 13 Sep 2022 New trial record
- 09 Sep 2022 Results published in the Infection